Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 6/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 5/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.42 |
| ▸ | QDPR | P09417 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | GRK2 | P25098 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781447 | 0.87 | QDPR (0.56) | EGFRABL1PTK6SRCPDE4B | |
| SCHEMBL17197274 | 0.86 | EGFR (0.52) | EGFRABL1PTK6SRCFYN | |
| SCHEMBL18764021 | 0.86 | EGFR (0.49) | EGFRPDE4BCAMK2DQDPRCHEK1 | |
| SCHEMBL3315978 | 0.83 | PDE4B (0.59) | PDE4BQDPRALK | |
| SCHEMBL12479659 | 0.83 | PDE4B (0.51) | PDE4BQDPRALK | |
| SCHEMBL27933804 | 0.82 | PDE4B (0.45) | EGFRABL1PTK6SRCFYN | |
| SCHEMBL17197372 | 0.81 | MEN1 (0.53) | EGFRPDE4BQDPR | |
| SCHEMBL17197365 | 0.81 | PDE4B (0.48) | EGFRABL1PTK6SRCFYN | |
| SCHEMBL18778503 | 0.80 | EGFR (0.56) | EGFRCAMK2DCHEK1ALK | |
| SCHEMBL1784746 | 0.79 | ALK (0.44) | EGFRABL1PDE4BCAMK2DQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | EGFR 1/4885ABL1 3/4885PTK6 33/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | EGFR 1/4885ABL1 3/4885PTK6 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.